Alumis (NASDAQ:ALMS) Downgraded to “Neutral” Rating by HC Wainwright

HC Wainwright lowered shares of Alumis (NASDAQ:ALMS) from a buy rating to a neutral rating in a research report report published on Friday morning, Marketbeat.com reports. They currently have $25.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the company. Raymond James Financial initiated coverage on Alumis in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Alumis in a research report on Monday, March 30th. Oppenheimer increased their price objective on shares of Alumis from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Stifel Nicolaus initiated coverage on shares of Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price objective on the stock. Finally, Loop Capital set a $37.00 price objective on shares of Alumis in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.10.

Alumis Trading Down 7.1%

Alumis stock opened at $22.87 on Friday. Alumis has a 12 month low of $2.76 and a 12 month high of $30.60. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -11.55 and a beta of -0.31. The business’s fifty day simple moving average is $24.44 and its two-hundred day simple moving average is $18.98.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.05. Alumis had a negative return on equity of 98.82% and a negative net margin of 2,825.70%.The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. On average, equities research analysts predict that Alumis will post -3.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. KBC Group NV bought a new position in Alumis in the first quarter valued at about $42,000. Strs Ohio lifted its holdings in Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after acquiring an additional 1,500 shares during the period. State of Wyoming bought a new position in Alumis in the first quarter valued at about $57,000. Assetmark Inc. bought a new position in Alumis in the first quarter valued at about $92,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after acquiring an additional 979 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.